Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma.

被引：0
|
作者：
Gounder, Mrinal M.
Rosen, Ezra
Parikh, Aparna Raj
Conley, Anthony Paul
Hong, David S.
Sheth, Siddharth
Mai, Nicholas
Sgroe, Erica
Mitchell, Ryan
Picard, Roxana
Brail, Les H.
Cote, Gregory Michael
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol & Oncol, Dept Med, Boston, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Erasca Inc, San Diego, CA USA
[6] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11522
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: a phase I study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
    McKean, Meredith
    Rosen, Ezra
    Barve, Minal
    Meniawy, Tarek
    Wang, Judy
    Hong, David S.
    Yang, Jennifer
    Li, Zhengrong
    Picard, Roxana
    Brail, Les
    Vecchio, Daniela
    John, Thomas
    Cohen, Ezra
    Obara, Gregory
    Parikh, Aparna
    CANCER RESEARCH, 2023, 83 (08)
  • [2] Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
    McKean, M.
    Barve, M.
    Hong, D.
    Parikh, A.
    Rosen, E.
    Yang, J.
    Picard, R.
    Yi, J.
    Brail, L.
    Vecchio, D.
    Meniawy, T.
    John, T.
    Wang, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S34 - S34
  • [3] Phase II study of taxotere monotherapy in previously treated patients (pts) with advanced breast cancer (ABC)
    Alexopoulos, CG
    Rigatos, G
    Efremidou, A
    Papacharalambous, A
    Alexopoulos, A
    Vasilomanolakis, M
    Patila, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 680 - 680
  • [4] Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC)
    Oh, D-Y.
    Arkenau, T.
    Lee, K-W.
    Alsina, M.
    Marti, F. M.
    Chung, I. J.
    Saif, W.
    Wang, D.
    O'Dwyer, P.
    Chau, I.
    Lee, M-A.
    Chong, E.
    Hilger-Rolfe, J.
    Cole, G., Jr.
    Kim, S. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S428 - S428
  • [5] Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
    Hellmann, Matthew D.
    Gettinger, Scott
    Chow, Laura Q. M.
    Gordon, Michael
    Awad, Mark M.
    Cha, Edward
    Gong, Xiaohua
    Zhou, Gongfu
    Walker, Chris
    Leopold, Lance
    Heist, Rebecca S.
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (07) : 1963 - 1969
  • [6] Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Preliminary results of cohort 1 of the phase 1 LITESPARK-010 study
    Sheng, Xinan
    Guo, Hongqian
    Yao, Xin
    Zhou, Fangjian
    Chen, Jimin
    Zhang, Shun
    Li, Juan
    Diao, Lei
    Dong, Pei
    Li, Xiaoqing
    Zhang, Zhewei
    Chain, Anne
    Zhu, Pengfei
    Zhang, Weijuan
    Wang, Ding
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study
    Doi, Toshihiko
    Yamamoto, Noboru
    Naito, Yoichi
    Kuboki, Yasutoshi
    Koyama, Takafumi
    Piao, Yongzhe
    Tsujimoto, Naoto
    Asou, Hiroya
    Inoue, Koichi
    Kondo, Shunsuke
    CANCER MEDICINE, 2021, 10 (19): : 6579 - 6589
  • [8] BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study
    Elamin, Yasir Y.
    Nagasaka, Misako
    Shum, Elaine
    Bazhenova, Lyudmila
    Camidge, D. Ross
    Cho, Byoung Chul
    Felip, Enriqueta
    Goto, Koichi
    Lin, Chia-Chi
    Piotrowska, Zofia
    Planchard, David
    Rotow, Julia K.
    Spigel, David R.
    Tan, Daniel Shao-Weng
    Yoshida, Tatsuya
    Minchom, Anna Rachel
    De langen, Adrianus
    Kato, Terufumi
    Zalutskaya, Alena
    Reckamp, Karen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer
    Wada, M.
    Yamamoto, M.
    Ryuge, S.
    Nagashima, Y.
    Hayashi, N.
    Maki, S.
    Otani, S.
    Katono, K.
    Takakura, A.
    Yanaihara, T.
    Igawa, S.
    Yokoba, M.
    Mitsufuji, H.
    Kubota, M.
    Katagiri, M.
    Masuda, N.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1005 - 1011
  • [10] Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer
    M. Wada
    M. Yamamoto
    S. Ryuge
    Y. Nagashima
    N. Hayashi
    S. Maki
    S. Otani
    K. Katono
    A. Takakura
    T. Yanaihara
    S. Igawa
    M. Yokoba
    H. Mitsufuji
    M. Kubota
    M. Katagiri
    N. Masuda
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1005 - 1011
12345